Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Filana Therapeutics, Inc. Common Stock

FLNA

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Last trade $0.4789
Day change +$0.0089 (+1.89%)
Day range $0.4652 – $0.492
Volume 478,805
Market cap $24M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$23.64M
Price / earnings
—
Price / book
0.41×
Price / sales
—
EV / sales
—
EV / EBITDA
0.53×

Profitability

Earnings per share
-$0.84
Return on assets
-42.17%
Return on equity
-72.79%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.91×
Quick ratio
1.91×
Cash ratio
1.12×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$29.13M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for FLNA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026
Revenue$0$0$0
Cost of revenue$0$0$0
Gross profit$0$0$0
Selling, general and administrative$7.41M$6.09M$6.62M
Research and development$3.87M$3.3M$4.54M
Total operating expenses$11.27M$9.39M$11.17M
Operating income-$11.27M-$9.39M-$11.17M
Interest expense$520K$747K$789K
Income before taxes-$10.73M-$8.6M-$10.33M
Income taxes$0$0$0
Net income-$10.73M-$8.6M-$10.33M
Net income attributable to common shareholders-$10.73M-$8.6M-$10.33M
EBITDA-$11.06M-$9.15M-$10.93M
Basic earnings per share-$0.22-$0.18-$0.21
Diluted earnings per share-$0.22-$0.18-$0.21

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Filana Therapeutics to Participate in the 2026 Maxim Growth Summit

Filana Therapeutics (NASDAQ: FLNA), a biotechnology company developing therapies for TSC-related epilepsy, announced that its management team will participate in the 2026 Maxim Growth Summit scheduled for October 12-14, 2026 in New York. The company will engage in one-on-one meetings at the event.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 20, 200510-for-1forward split